§ Claim under review · Health
"Scientists have officially created the world's first drug capable of making memory up to 70% younger in just 48 hours." Caption: ISRIB "was tested on mice, and the results were astonishing: animals suffering from learning impairments or brain injuries regained the ability to remember up to 70% more routes, locations, and complex tasks only two days after treatment." Sourced to "ScienceDaily – Drug shows rapid improvement in memory and cognition" and to "a report published in Science."
Verdict
Partially accurate but misleading
Confidence
HighSummary
ISRIB is a real experimental drug discovered at UC San Francisco in 2013, and real peer-reviewed studies did show it rapidly improved memory and maze performance in old mice and in mice with brain injuries. But the viral post's key details do not hold up. No study, press release, or news article contains the "70 percent younger memory" figure, and maze experiments are not measured that way. The post says its source is a ScienceDaily article, but that article is from February 2025 and is about a different drug called GL-II-73, not ISRIB. The post also says the research appeared in the journal Science, when the memory results were published in eLife and PNAS. Most importantly, ISRIB has never been tested for memory or cognition in humans, is not approved anywhere, and is not a supplement, so the post's promotion of supplement links has no connection to this research. What remains genuinely uncertain is whether inhibiting this cellular stress pathway helps human cognition at all, since current human trials of related compounds are studying ALS safety and biomarkers rather than memory.
The readings
key figures from the evidenceclaimed memory improvement in the viral post
claimed time for memory to become younger
year ISRIB was discovered at UCSF
Why this verdict
Evidence
ISRIB is a real molecule. The ISRIB drug was discovered in 2013 in the laboratory of Peter Walter.
It works by binding to a central cellular player involved in translation, allowing stressed cells to override the integrated stress response so that protein translation proceeds.
The aging study the post is loosely describing was published in eLife in December 2020, not in Science. It reported that ISRIB reverses ISR activation in the brain, as indicated by decreased ATF4 and phosphorylated eIF2, and that ISRIB treatment reverses spatial memory deficits and ameliorates working memory in old mice.
The actual experiment: researchers trained aged mice to escape a watery maze by finding a hidden platform, a task typically hard for older animals; animals given small daily doses of ISRIB during the three-day training process performed as well as youthful mice and much better than untreated animals of the same age. Several weeks later the same mice were tested on a maze whose exit changed daily, and those that had received brief ISRIB treatment three weeks earlier still performed at youthful levels.
On the speed question, the team examined hippocampal cells one day after a single dose and found common signatures of neuronal aging disappeared overnight, with neurons becoming more responsive to stimulation and showing more robust connectivity.
Separately, in traumatic brain injury work, treatment with ISRIB corrected TBI-induced memory deficits when administered weeks after the initial injury and maintained cognitive improvement after treatment.
No source located contains a "70 percent" figure, and no source describes memory being made "70% younger." The cited ScienceDaily article is about a different drug entirely:
a study showing GL-II-73 has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease.
Findings
✓ What's accurate 5
- ISRIB exists and is a real, well-documented research compound from UCSF.
- Its mechanism is accurately described in general terms: it inhibits the integrated stress response, a cellular stress pathway.
- It was tested in mice with age-related learning deficits and in mice with traumatic brain injury, and improved memory performance in both.
- Effects were unusually rapid. Cellular changes were observed one day after a single dose, and behavioral benefit followed a three-day dosing window.
- Researchers have publicly framed it as relevant to future work on cognitive decline.
≈ What's misleading 7
- Fabricated or untraceable statistic: the "70% younger" and "70% more routes, locations, and complex tasks" figures appear in no primary paper, no university release, and no news coverage found. Maze studies do not report results in that form.
- False source attribution: the cited ScienceDaily link is a February 2025 article about GL-II-73 from the Centre for Addiction and Mental Health, not about ISRIB.
- Wrong journal: the memory findings were published in eLife (2020) and PNAS (2017). Science has published ISRIB mechanism and structural work, not the mouse memory results.
- Species extrapolation: mouse results are presented as a drug that makes "memory" younger, with no qualification that no human cognitive trial exists.
- Temporal overreach and novelty framing: "officially created" and "world's first" imply a new, finished product. The discovery is from 2013 and the aging paper is from 2020, and ISRIB has never been approved for anything.
- Omitted qualifier: the "48 hours" figure blurs a three-day dosing protocol and overnight cellular changes into a claim about memory rejuvenation in two days.
- Marketing context: the post uses the claim to direct readers to supplement links. ISRIB is not a supplement and is not an ingredient in any approved or marketed supplement.
? What's uncertain 3
- Whether the "70%" figure originated from a misreading of a specific figure in a paper, from another article, or was invented outright. No trace of it was found, but absence of a finding is not proof of non-existence.
- Exact wording of what the post's images stated beyond the OCR text provided.
- Whether ISR inhibition will produce cognitive benefit in humans. Current human trials of the drug class target ALS biomarkers, not memory.
Sources
5 of 6 linked to recordsKrukowski et al., "Small molecule cognitive enhancer reverses age-related memory decline in mice," eLife, Dec 1 2020
UCSF news release, "Drug Reverses Age-Related Mental Decline Within Days," Dec 1 2020
Chou et al., "Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury," PNAS 2017
ScienceDaily, Feb 4 2025, "New drug shows promise in reversing memory loss for early Alzheimer's patients"
Flores et al., Nature Communications, Aug 2025, DNL343 Phase 1/1b in ALS
eLife 2024, DNL343 characterization paper, describing ISRIB's development limitations